Theodore E. Hebert

Array ( [id] => 15147867 [patent_doc_number] => 20190352411 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => Novel Anti-CD137 Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/461544 [patent_app_country] => US [patent_app_date] => 2017-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25216 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -65 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16461544 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17206657 [patent_doc_number] => 11167008 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-09 [patent_title] => Immunomodulatory and oncolytic minicells and methods of use [patent_app_type] => utility [patent_app_number] => 15/820063 [patent_app_country] => US [patent_app_date] => 2017-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 19402 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15820063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16183516 [patent_doc_number] => 10716809 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-21 [patent_title] => Methods of producing enriched populations of tumor reactive T cells from peripheral blood [patent_app_type] => utility [patent_app_number] => 15/813398 [patent_app_country] => US [patent_app_date] => 2017-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 9 [patent_no_of_words] => 6004 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15813398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12580920 [patent_doc_number] => 20180085469 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER [patent_app_type] => utility [patent_app_number] => 15/812562 [patent_app_country] => US [patent_app_date] => 2017-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54824 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15812562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13300289 [patent_doc_number] => 20180201681 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => ANTI-CD83 ANTIBODIES AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/808423 [patent_app_country] => US [patent_app_date] => 2017-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27519 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15808423 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15209837 [patent_doc_number] => 20190367605 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => Binding Molecules Specific For ASCT2 And Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/346612 [patent_app_country] => US [patent_app_date] => 2017-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30903 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16346612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12259421 [patent_doc_number] => 20180078617 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-22 [patent_title] => 'ANTI-CELL PROLIFERATIVE COMPOUNDS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/804881 [patent_app_country] => US [patent_app_date] => 2017-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 20801 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15804881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12681823 [patent_doc_number] => 20180119107 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => METHODS TO PRESERVE TUMOR-STROMAL INTERACTIONS IN CULTURE AND THERAPEUTIC PREDICTIVE APPLICATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 15/793249 [patent_app_country] => US [patent_app_date] => 2017-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11102 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15793249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12184067 [patent_doc_number] => 20180043003 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'REAGENTS AND METHODS FOR IDENTIFYING, ENRICHING, AND/OR EXPANDING ANTIGEN-SPECIFIC T CELLS' [patent_app_type] => utility [patent_app_number] => 15/790787 [patent_app_country] => US [patent_app_date] => 2017-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 19745 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15790787 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12657043 [patent_doc_number] => 20180110847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-26 [patent_title] => Immunotherapy of Cancer by Induction of Immunologically-Mediated Selective Killing of Tumor Vasculature Using Modified Endothelial Cells and Progenitors Thereof [patent_app_type] => utility [patent_app_number] => 15/789260 [patent_app_country] => US [patent_app_date] => 2017-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12974 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15789260 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15451313 [patent_doc_number] => 20200038480 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => METHODS AND COMPOSITIONS FOR TUSC2 IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/341134 [patent_app_country] => US [patent_app_date] => 2017-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23276 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16341134 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12160294 [patent_doc_number] => 20180031560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'BIOMARKER FOR DETECTING CANCER' [patent_app_type] => utility [patent_app_number] => 15/726123 [patent_app_country] => US [patent_app_date] => 2017-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 14865 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15726123 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12773467 [patent_doc_number] => 20180149657 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-31 [patent_title] => ISOLATION, DETECTION, DIAGNOSIS AND/OR CHARACTERIZATION OF CIRCULATING TROP-2-POSITIVE CANCER CELLS [patent_app_type] => utility [patent_app_number] => 15/707404 [patent_app_country] => US [patent_app_date] => 2017-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25923 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -49 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15707404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12151542 [patent_doc_number] => 20180022806 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-25 [patent_title] => 'MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS' [patent_app_type] => utility [patent_app_number] => 15/704790 [patent_app_country] => US [patent_app_date] => 2017-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 25942 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15704790 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16761036 [patent_doc_number] => 20210106617 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2021-04-15 [patent_title] => COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 15/685086 [patent_app_country] => US [patent_app_date] => 2017-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 87710 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15685086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16761036 [patent_doc_number] => 20210106617 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2021-04-15 [patent_title] => COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 15/685086 [patent_app_country] => US [patent_app_date] => 2017-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 87710 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15685086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16259876 [patent_doc_number] => 10751284 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-08-25 [patent_title] => Targeted therapy to deplete tumor-associated macrophages (TAMs) [patent_app_type] => utility [patent_app_number] => 15/677555 [patent_app_country] => US [patent_app_date] => 2017-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 5 [patent_no_of_words] => 6531 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15677555 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13699631 [patent_doc_number] => 20170360770 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => EFFICACY OF ANTI-HLA-DR ANTIBODY DRUG CONJUGATE IMMU-140 (hL243-CL2A-SN-38) IN HLA-DR POSITIVE CANCERS [patent_app_type] => utility [patent_app_number] => 15/669264 [patent_app_country] => US [patent_app_date] => 2017-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26769 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15669264 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14406913 [patent_doc_number] => 20190169300 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => COMBINATION OF GLUCAGON RECEPTOR ANTAGONISTS AND PI3K PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/322964 [patent_app_country] => US [patent_app_date] => 2017-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30939 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16322964 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13276665 [patent_doc_number] => 10149898 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-11 [patent_title] => Methods and compositions for the treatment of melanoma [patent_app_type] => utility [patent_app_number] => 15/668451 [patent_app_country] => US [patent_app_date] => 2017-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 17009 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15668451 [rel_patent_id] =>[rel_patent_doc_number] =>)